Companies and People News for October 2009

Companies and People News Archive

Bicycle Therapeutics, a new Medical Research Council (MRC) UK spin-out, secures seed funding from top venture capital firms to develop novel constrained cyclic peptides as therapeutic agents. Bicycle Therapeutics, a new Medical Research Council (MRC) UK spin-out, secures seed funding from top venture capital firms to develop novel constrained cyclic peptides as therapeutic agents.

A new spin out company from the Medical Research Council’s Laboratory of Molecular Biology in Cambridge UK was announced this week. Bicycle Therapeutics is a new biotechnology company developing a novel technology platform for the creation of a new class of therapeutic entity which combines the most desirable features of small molecules and biologics.

ELRIG Sponsors ‘Technobotts’, young innovators competing in the RoboCup 2010 in Singapore ELRIG Sponsors ‘Technobotts’, young innovators competing in the RoboCup 2010 in Singapore

ELRIG (The European Laboratory Robotic Interest Group) has a mission to give back to the Industry whenever they can and to encourage the growth of Innovative Technology. It was therefore very appropriate that they agreed to Sponsor the Technobotts in their venture to enter the RoboCup 2010 in Singapore.

Integrated Diagnostics launches with pre-eminent team and investors Integrated Diagnostics launches with pre-eminent team and investors

Dr Leroy Hood-led venture has secured $30 million Series A financing from InterWest Partners, Wellcome Trust and dievini.

Trophos' olesoxime selected by Thomson Reuters’ ‘Ones to Watch’ Report as a top five Phase III product Trophos' olesoxime selected by Thomson Reuters’ ‘Ones to Watch’ Report as a top five Phase III product

Olesoxime in ongoing pivotal efficacy study for amyotrophic lateral sclerosis.

BioFocus launches SilenceSelect microsite BioFocus launches SilenceSelect microsite

BioFocus has recently launched its new microsite, www.SilenceSelect.com, which is dedicated to the SilenceSelect® and FLeXSelect® adenoviral technology.

Merck and QIAGEN collaborate to accelerate access to cervical cancer vaccination and screening in developing countries Merck and QIAGEN collaborate to accelerate access to cervical cancer vaccination and screening in developing countries

Major new collaboration announced at Clinton Global Initiative Annual Meeting.

Sanofi-aventis to acquire Fovea Pharmaceuticals Sanofi-aventis to acquire Fovea Pharmaceuticals

Sanofi-aventis announced recently that it has signed a binding agreement for the acquisition of Fovea Pharmaceuticals SA (‘Fovea‘), a privately held French research and development biopharmaceutical company, focused on ocular diseases.

Abbott wins bidding war for Solvay Abbott wins bidding war for Solvay

Multi-disciplinary healthcare giant Abbott Laboratories has fought off competition from Nycomed to secure the $6.6 billion acquisition of Solvay's pharmaceutical business.